Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
暂无分享,去创建一个
[1] M. Kogevinas,et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study , 2007, BMC urology.
[2] Inflammatory issue. , 2007, Nursing older people.
[3] J. Verweij,et al. Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients , 2004, Clinical Cancer Research.
[4] A. Kimball,et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005–09 , 2014, The British journal of dermatology.
[5] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[6] R. Benya,et al. Randomized Phase II Trial of Sulindac, Atorvastatin, and Prebiotic Dietary Fiber for Colorectal Cancer Chemoprevention , 2011, Cancer Prevention Research.
[7] W. Liao,et al. An update on drug–drug interactions with biologics for the treatment of moderate-to-severe psoriasis , 2014, The Journal of dermatological treatment.
[8] J. Kirkwood,et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] W. Paul,et al. How are TH2-type immune responses initiated and amplified? , 2010, Nature Reviews Immunology.
[10] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[11] M. Błasińska-Morawiec,et al. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer. , 2009, Clinical breast cancer.
[12] T. Lynch,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] S. Akira,et al. Identification and functions of pattern-recognition receptors. , 2010, The Journal of allergy and clinical immunology.
[14] M. Smyth,et al. Immune surveillance of tumors. , 2007, The Journal of clinical investigation.
[15] T. Mason,et al. Analgesic therapy and the prevention of bladder cancer. , 2004, Urologic oncology.
[16] A. Hauschild,et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Pavlick,et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma , 2011, Investigational New Drugs.
[18] L. Lashinger,et al. The growing challenge of obesity and cancer: an inflammatory issue , 2011, Annals of the New York Academy of Sciences.
[19] I. Jang,et al. Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance , 2013, Clinical pharmacology and therapeutics.
[20] G. Hämmerling,et al. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. , 2008, The Journal of clinical investigation.
[21] David A. Smith,et al. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. , 2011, Clinical colorectal cancer.
[22] S. Rosenberg,et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.
[23] F. Jamali,et al. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. , 2009, Basic & clinical pharmacology & toxicology.
[24] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[25] E. Morgan. Regulation of cytochrome p450 by inflammatory mediators: why and how? , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[26] S. Kritchevsky,et al. Circulating Levels of Inflammatory Markers and Cancer Risk in the Health Aging and Body Composition Cohort , 2005, Cancer Epidemiology Biomarkers & Prevention.
[27] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[28] B. Fox,et al. Signaling through OX40 enhances antitumor immunity. , 2010, Seminars in oncology.
[29] G. Botti,et al. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma , 2013, Journal of Translational Medicine.
[30] P. Ascierto,et al. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.
[31] P. Beaune,et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. , 1999, Biochemical pharmacology.
[32] R. Harvey. Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer , 2014, Clinical pharmacology and therapeutics.
[33] P. Maurel,et al. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture , 1995, Hepatology.
[34] S. Dallas,et al. Interleukins-12 and -23 Do Not Alter Expression or Activity of Multiple Cytochrome P450 Enzymes in Cryopreserved Human Hepatocytes , 2013, Drug Metabolism and Disposition.
[35] Michael Y. Gerner,et al. Cutting Edge: IL-12 and Type I IFN Differentially Program CD8 T Cells for Programmed Death 1 Re-expression Levels and Tumor Control , 2013, The Journal of Immunology.
[36] J. Wolchok,et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit , 2008, Proceedings of the National Academy of Sciences.
[37] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[38] C. Janeway,et al. Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.
[39] B. Kuhn,et al. Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis , 2011, Clinical pharmacology and therapeutics.
[40] Rohini Sharma,et al. Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signalling , 2013, Pharmaceutical Research.
[41] P. Heinrich,et al. Hepatic cytochrome P450 down‐regulation during aseptic inflammation in the mouse is interleukin 6 dependent , 2000, Hepatology.
[42] S. Clarke,et al. Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer , 2006, Clinical Cancer Research.
[43] Sui Huang,et al. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer , 2010, Cancer and Metastasis Reviews.
[44] Jashin J. Wu,et al. Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy. , 2011, Cutis (New York, N.Y.).
[45] ET Morgan,et al. Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics , 2009, Clinical pharmacology and therapeutics.
[46] A. Tsao. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study , 2012 .
[47] Jane R Kenny,et al. Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper , 2013, Drug Metabolism and Disposition.
[48] J. Williams,et al. IN A POPULATION-BASED CASE-CONTROL STUDY , 2001 .
[49] W. Lutz,et al. Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[50] S. Clarke,et al. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing , 2008, Expert opinion on drug metabolism & toxicology.
[51] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[52] H. Pehamberger,et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] J. Gaziano,et al. Low-Dose Aspirin in the Primary Prevention of Cancer. The Women’s Health Study: A Randomized Controlled Trial , 2005 .
[54] C. Printz. Spontaneous regression of melanoma may offer insight into cancer immunology. , 2001, Journal of the National Cancer Institute.
[55] A. Kashuba,et al. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[56] S. Poloyac,et al. Activation of the Acute Inflammatory Response Alters Cytochrome P450 Expression and Eicosanoid Metabolism , 2011, Drug Metabolism and Disposition.
[57] M. Goldman,et al. Interleukin-10 , 2012, BioDrugs.
[58] S. Steinberg,et al. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.
[59] B. Beutler,et al. Intracellular toll-like receptors. , 2010, Immunity.
[60] J. Wolchok,et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. , 2013, Cancer immunity.
[61] Jun Hee Lee,et al. Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.
[62] N. Vogelzang,et al. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. , 1992, The Journal of urology.
[63] S. Clarke,et al. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response , 2002, British Journal of Cancer.
[64] T. A. Richardson,et al. Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.
[65] J. Cany,et al. Agonistic anti‐CD137 antibody treatment leads to antitumor response in mice with liver cancer , 2014, International journal of cancer.
[66] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[67] C. Punt,et al. PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer , 2012, Journal of immunotherapy.
[68] D. Woolley,et al. The white paper , 1943, Public Health.
[69] L. Corcos,et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. , 1993, Molecular pharmacology.
[70] Micheline Piquette-Miller,et al. Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer , 2008, Drug Metabolism and Disposition.
[71] J. Neal,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] S. Akira,et al. Pattern Recognition Receptors and Inflammation , 2010, Cell.
[73] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[74] Edward T. Morgan,et al. Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes , 2007, Drug Metabolism and Disposition.
[75] A. Doseff,et al. Monocytes and Macrophages Regulate Immunity through Dynamic Networks of Survival and Cell Death , 2010, Journal of Innate Immunity.
[76] S. Wahl,et al. Antagonistic and agonistic effects of transforming growth factor-beta and IL-1 in rheumatoid synovium. , 1990, Journal of immunology.
[77] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[78] P. Ascierto,et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. , 2012, The Lancet. Oncology.
[79] E. Morgan,et al. Modulation of Hepatic Cytochrome P450s by Citrobacter rodentium Infection in Interleukin-6- and Interferon-γ-Null Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.
[80] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.